المؤلفون: Beckermann, Kathryn, Rini, Brian, Aftab, Blake T, Budworth, Helen, Galimi, Francesco, Green, Shon, Jahchan, Nadine, Kennedy-Wilde, Jackie, Nishimoto, Kevin P, Vosganian, Gregory S, Ye, Yining, Garmezy, Benjamin, Pal, Sumanta

المصدر: Regular and Young Investigator Award Abstracts ; page A734-A737

الاتاحة: https://doi.org/10.1136/jitc-2024-sitc2024.0640
https://syndication.highwire.org/content/doi/10.1136/jitc-2024-SITC2024.0640

المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

المساهمون: HUS Comprehensive Cancer Center, Department of Oncology

مصطلحات موضوعية: Budigalimab, Head and neck squamous cell cancer, Non-small cell lung cancer, PD-1 inhibitor, Cancers

وصف الملف: application/pdf

Relation: AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. AbbVie and the authors thank the patients who participated in this clinical trial, the study coordinators, and support staff. We would like to acknowledge James P. Sheridan (Drug Metabolism Pharmacokinetics & Bioanalysis Department, AbbVie) for performing the preclinical and clinical pharmacokinetic studies, and Fiona Harding (Oncology Discovery, AbbVie) for creating, selecting, and validating the ABBV-181 antibody and filing the in vitro/in vivo IND supporting reports, including summaries of the preclinical activity of ABBV-181. Biomarker sample testing was performed by Covance, Princeton, NJ (flow cytometry), Mosaic Laboratories, Lake Forest, CA (immunohistochemistry), and Myriad RBM, Austin, TX (cytokine testing). This study was funded by AbbVie Inc., North Chicago, IL, USA. Medical writing support was provided by Joanne Franklin, PhD, CMPP, Aptitude Health, The Hague, the Netherlands, funded by AbbVie. Antoine Italiano: Consulting/advisory role: Roche, Daiichi Sankyo, Immune Design, Epizyme, Bayer, Lilly; honoraria: Bayer, Daiichi Sankyo, Lilly, Epizyme, Novartis, Roche; research funding: Roche, Bayer, AstraZeneca/MedImmune, PharmaMar, MSD Oncology, Merck Serono. Philippe A. Cassier: Honoraria: Novartis, Roche/Genentech, Blueprint Medicines, Amgen; research funding: Novartis, Roche/Genentech, Lilly, Blueprint Medicines, Bayer, AstraZeneca, Celgene, Plexxikon, AbbVie, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme; Consultancy/advisory role: Merck Serono, Roche/Genentech. Chia-Chi Lin: Consulting/advisory role: Novartis, Boehringer Ingelheim, Blueprint Medicines; travel/accommodations/expenses: Lilly, Daiichi Sankyo, BeiGene, Novartis; honoraria: Novartis, Roche, Daiichi Sankyo. Tuomo Alanko: Consulting/advisory role: Bayer, Baxalta/Shire, BMS, Celgene, Eli Lilly, MSD, Nordic Drugs, Roche, Kaiku Health; research funding: AbbVie, Bayer, Boehringer Ingelheim, BMS, Debiopharm, Eli Lilly, Incyte, MSD, Pfizer, Roche; travel/accommodations/expenses: Baxalta/Shire, BMS, MSD, Pfizer, Roche. Katriina J. Peltola: Consulting/advisory role: Orion Pharma, BMS, MSD, Novartis, Pfizer, Ipsen, Roche, Varian; stockholder: Faron Pharmaceuticals; speakers’ bureau: BMS, Pfizer, MSD; expert testimony: Ipsen; travel/accommodations/expenses: Roche, BMS; research funding: AbbVie, Bayer, BMS, MSD, Roche, Exelixis, Orion Pharma, Eisai, Novartis. Anas Gazzah: Travel, accommodations, congress registration expenses: Boehringer Ingelheim, Novartis, Pfizer, Roche; consultant/expert role: Novartis; principal/sub-investigator of clinical trials: Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer HealthCare Ag, BBB Technologies BV, BeiGene, BioAlliance Pharma, BioNTech AG, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm SA, Eisai, Exelixis, Forma, GamaMabs, Genentech, Inc., Gilead Sciences, Inc, GlaxoSmithKline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, F. Hoffmann-La Roche AG, Incyte Corporation, Innate Pharma, Servier IRIS, Janssen, Kura Oncology, Kyowa Kirin Pharmaceutical Development, Lilly, Loxo Oncology, Lytix Biopharma AS, MedImmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, OncoEthix, OncoMed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, PharmaMar, Pierre Fabre, Rigontec GmbH, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor; research grants: AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; nonfinancial support (drug supplied): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, MedImmune, Merck, NH TherAGuix, Pfizer, Roche. Her-Shyong Shiah: The author declares no potential conflicts of interest. Emiliano Calvo: Consulting/advisory role: Novartis, Nanobiotix, Janssen-Cilag, PsiOxus, Seattle Genetics, EUSA Pharma, AbbVie, Celgene, AstraZeneca, Guidepoint Global, Roche/Genentech, GLG, Pfizer, Servier, amcure; speakers’ bureau: Novartis; research funding: AstraZeneca, BeiGene, Novartis, START; travel/accommodations/expenses reimbursement: Roche/Genentech; honoraria: HM Hospitales Group; stock/ownership interests: START, Oncoart Associated, International Cancer Consultants; president and founder of Foundation INTHEOS . Andrés Cervantes: Institutional research funding: AbbVie, Genentech, Merck Serono, BMS, MSD, Roche, BeiGene, Bayer, Servier, Lilly, Novartis, Takeda, Astellas, FibroGen; advisory board or speaker fees: Merck Serono, Roche, Bayer, Servier, Pierre Fabre. Desamparados Roda: The author declares no potential conflicts of interest. Diego Tosi: Consulting/advisory role: BioMarin (immediate family member); research funding: Novartis, Astellas, Janssen; patent pending on a new drug combination for prostate cancer treatment; travel/accommodations/expenses: Janssen, Pfizer, Astellas Pharma; immediate family member had travel/accommodations/expenses from Nutricia and Amicus. Bo Gao: Consulting/advisory role: MSD. Michael Millward: Consulting/advisory role: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche, Pfizer, Takeda, Novartis; conference travel/support: Merck Sharp & Dohme, Bristol-Myers Squibb, AstraZeneca, Roche. Lydia Warburton: Travel/accommodations/expenses: MSD, Merck. Minna Tanner: Consulting/advisory role: Roche, Novartis, Pfizer; speakers’ bureau: Roche, Novartis, Pfizer, Amgen. Gregory Vosganian: Former employee of AbbVie and may own stock. Stefan Englert, Stacie Lambert, Apurvasena Parikh, Daniel E. Afar: AbbVie employees and may own stock. Victor Moreno: Consulting fees: Merck, BMS, Janssen, Pieris; travel/accommodations: Regeneron/Sanofi; presentations: Nanobiotix; educational grant: Medscape/Bayer.; Italiano , A , Cassier , P A , Lin , C-C , Alanko , T , Peltola , K J , Gazzah , A , Shiah , H-S , Calvo , E , Cervantes , A , Roda , D , Tosi , D , Gao , B , Millward , M , Warburton , L , Tanner , M , Englert , S , Lambert , S , Parikh , A , Afar , D E , Vosganian , G & Moreno , V 2022 , ' First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma ' , Cancer Immunology, Immunotherapy , vol. 71 , no. 2 , pp. 417-431 . https://doi.org/10.1007/s00262-021-02973-w; http://hdl.handle.net/10138/354706; 82232dae-2a73-44eb-98d3-0e87d81835e0; 85109344549

الاتاحة: http://hdl.handle.net/10138/354706

المؤلفون: Palandri, Francesca, Gröpper, Stefanie, Loschi, Michael, Bellesso, Marcelo, Grosicki, Sebastian, Giraldo, Pilar, Harrison, Claire, Clevenger, Tracy, Stuart, Nikki, Qamoos, Hope, Vosganian, Gregory, Rothbaum, Wayne P., Verstovsek, Srdan, Vachhani, Pankit

المصدر: HemaSphere ; volume 7, issue S3, page e0110210 ; ISSN 2572-9241

الاتاحة: http://dx.doi.org/10.1097/01.hs9.0000975544.01102.10
https://journals.lww.com/10.1097/01.HS9.0000975544.01102.10

المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory, Moreno, Victor

المساهمون: Tampere University, Department of Oncology

مصطلحات موضوعية: 3122 Cancers

وصف الملف: fulltext

Relation: Cancer Immunology, Immunotherapy; https://trepo.tuni.fi/handle/10024/133491

الاتاحة: https://trepo.tuni.fi/handle/10024/133491
https://doi.org/10.1007/s00262-021-02973-w

المؤلفون: Calvo, Emiliano, Spira, Alexander, Miguel, María de, Kondo, Shunsuke, Gazzah, Anas, Millward, Michael, Prenen, Hans, Rottey, Sylvie, Warburton, Lydia, Alanko, Tuomo, Cassier, Philippe A., Yoh, Kiyotaka, Italiano, Antoine, Moreno, Victor, Peltola, Katriina, Seto, Takashi, Toyozawa, Ryo, Afar, Daniel E., Englert, Stefan, Komarnitsky, Philip, Lambert, Stacie, Parikh, Apurvasena, Vosganian, Gregory, Gao, Bo

المصدر: CANCER TREATMENT AND RESEARCH COMMUNICATIONS ; ISSN: 2468-2942

مصطلحات موضوعية: Medicine and Health Sciences, Cancer Research, Oncology

وصف الملف: application/pdf

Relation: https://biblio.ugent.be/publication/8730498; http://hdl.handle.net/1854/LU-8730498; http://dx.doi.org/10.1016/j.ctarc.2021.100405; https://biblio.ugent.be/publication/8730498/file/8730499

الاتاحة: https://biblio.ugent.be/publication/8730498
http://hdl.handle.net/1854/LU-8730498
https://doi.org/10.1016/j.ctarc.2021.100405
https://biblio.ugent.be/publication/8730498/file/8730499

المؤلفون: Powderly, John, Spira, Alexander, Kondo, Shunsuke, Doi, Toshihiko, Luke, Jason J., Rasco, Drew, Gao, Bo, Tanner, Minna, Cassier, Philippe A., Gazzah, Anas, Italiano, Antoine, Tosi, Diego, Afar, Daniel E., Parikh, Apurvasena, Engelhardt, Benjamin, Englert, Stefan, Lambert, Stacie L., Kasichayanula, Sreeneeranj, Mensing, Sven, Menon, Rajeev, Vosganian, Gregory, Tolcher, Anthony

المساهمون: AbbVie

المصدر: Clinical and Translational Science ; volume 14, issue 1, page 277-287 ; ISSN 1752-8054 1752-8062

الاتاحة: http://dx.doi.org/10.1111/cts.12855
https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fcts.12855
https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12855
https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cts.12855
https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12855

المؤلفون: Vosganian, Gregory S, Sigal, Darren S, Saven, Alan

المصدر: Expert Review of Hematology ; volume 3, issue 6, page 679-683 ; ISSN 1747-4086 1747-4094

الاتاحة: http://dx.doi.org/10.1586/ehm.10.67
http://www.tandfonline.com/doi/pdf/10.1586/ehm.10.67

المؤلفون: Italiano, Antoine, Cassier, Philippe A., Lin, Chia-Chi, Alanko, Tuomo, Peltola, Katriina J., Gazzah, Anas, Shiah, Her-Shyong, Calvo, Emiliano, Cervantes, Andrés, Roda, Desamparados, Tosi, Diego, Gao, Bo, Millward, Michael, Warburton, Lydia, Tanner, Minna, Englert, Stefan, Lambert, Stacie, Parikh, Apurvasena, Afar, Daniel E., Vosganian, Gregory

المصدر: Cancer Immunology, Immunotherapy; Feb2022, Vol. 71 Issue 2, p417-431, 15p

مصطلحات موضوعية: NON-small-cell lung carcinoma, PEMBROLIZUMAB, HEAD & neck cancer, SQUAMOUS cell carcinoma, INTERFERON gamma

المؤلفون: Vosganian, Gregory S., Bos, Rinke, Sherman, Linda A.

المصدر: Journal of Immunotherapy ; volume 35, issue 6, page 473-477 ; ISSN 1524-9557

الاتاحة: http://dx.doi.org/10.1097/cji.0b013e3182618209
https://journals.lww.com/10.1097/CJI.0b013e3182618209

المؤلفون: Vosganian, Gregory S., Waalen, Jill, Kim, Kevin, Jhatakia, Sejal, Schram, Ethan, Lee, Tracey, Riddell, Dan, Mason, James R.

المصدر: Cytotherapy ; volume 14, issue 10, page 1228-1234 ; ISSN 1465-3249

الاتاحة: http://dx.doi.org/10.3109/14653249.2012.706707
https://api.elsevier.com/content/article/PII:S1465324912712410?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S1465324912712410?httpAccept=text/plain

المؤلفون: Vosganian, Gregory S., Boisot, Saskia, Hartmann, Kathrin I., Freeman, William R., Sharpe, Robert W., Tripuraneni, Prabhakar, Saven, Alan

المصدر: Journal of Neuro-Oncology ; volume 105, issue 2, page 127-134 ; ISSN 0167-594X 1573-7373

الاتاحة: http://dx.doi.org/10.1007/s11060-011-0618-1
http://link.springer.com/content/pdf/10.1007/s11060-011-0618-1.pdf
http://link.springer.com/article/10.1007/s11060-011-0618-1/fulltext.html
http://link.springer.com/content/pdf/10.1007/s11060-011-0618-1

المؤلفون: Flinn, Ian W., Brunvand, Mark, Choi, Michael Y., Dyer, Martin J.S., Gribben, John, Hillmen, Peter, Jones, Jeffrey, Li, Yan, Mobasher, Mehrdad, Vosganian, Gregory, Kipps, Thomas J.

المصدر: Blood; December 2015, Vol. 126 Issue: 23 p494-494, 1p

المؤلفون: Flinn, Ian, Brunvand, Mark, Dyer, Martin JS, Hillman, Peter, Jones, Jeffrey, Lymp, James, Elhamy, Mostafa, Vosganian, Gregory, Huang, Jane, Kipps, Thomas J.

المصدر: Blood; December 2014, Vol. 124 Issue: 21 p4687-4687, 1p

المؤلفون: Salles, Gilles Andre, Boyd, Thomas E, Morschhauser, Franck, Wendtner, Clemens-Martin, Lymp, James, Hilger, James, Vosganian, Gregory, Huang, Jane, Stilgenbauer, Stephan

المصدر: Blood; December 2014, Vol. 124 Issue: 21 p3337-3337, 1p

المؤلفون: Vosganian, Gregory S., Bos, Rinke, Sherman, Linda

المصدر: Blood; November 2011, Vol. 118 Issue: 21 p4935-4935, 1p